Journal Title
Title of Journal: Ann Hematol
|
Abbravation: Annals of Hematology
|
Publisher
Springer-Verlag
|
|
|
|
Authors: Simone Oerlemans Olga Husson Floortje Mols Philip Poortmans Henk Roerdink Laurien A Daniels Carien L Creutzberg Lonneke V van de PollFranse
Publish Date: 2012/05/26
Volume: 91, Issue: 10, Pages: 1587-1595
Abstract
To improve posttreatment care for longterm lymphoma survivors in the Netherlands survivorship clinics are being developed As information provision is an important aspect of survivorship care our aim was to evaluate the current perceived level of and satisfaction with information received by nonHodgkin’s lymphoma NHL Hodgkin’s lymphoma HL and multiple myeloma MM survivors and to identify associations with sociodemographic and clinical characteristics The populationbased Eindhoven Cancer Registry was used to select all patients diagnosed with NHL HL and MM from 1999 to 2009 In total 1448 survivors received a questionnaire and 1135 of them responded 784 The EORTC QLQINFO25 was used to evaluate the perceived level of and satisfaction with information Two thirds of survivors were satisfied with the amount of received information with HL survivors being most satisfied 74 At least 25 of survivors wanted more information Young age having had chemotherapy having been diagnosed more recently using internet for information and having no comorbidities were the most important factors associated with higher perceived levels of information provision Although information provision and satisfaction with information seems relatively good in lymphoma and MM survivors one third expressed unmet needs Furthermore variations between subgroups were observed Good information provision is known to be associated with better quality of life Survivorship care plans could be a way to achieve thisOn January 1 2009 there were approximately 21000 nonHodgkin lymphoma NHL 5300 Hodgkin lymphoma HL and 3300 multiple myeloma MM survivors in the Netherlands 1 These numbers are expected to increase to approximately 32000 NHL 6300 HL and 4300 MM survivors by 2020 1 This substantial rise will result in an increasing health care burden in haematology especially indolent lymphomas and MM which both are characterised by a prolonged clinical course with repeated relapses and slow but ongoing progression 2To improve care for this growing group of cancer survivors a nationwide initiative of haematologists radiation oncologists epidemiologists and internists has founded a Working Group named “BETTER” “BETER” in Dutch which is currently developing protocols for standardized longterm care for HL and NHL survivors and establishing survivorship clinics The goals of these clinics are to minimize the occurrence and influence of late effects and to improve survivors’ quality of life QoL by informing survivors about longterm risks advice preventive measures suggest screening and improve aftercare by providing rehabilitation programmes 3Patient information is an essential component of cancer care and rehabilitation 4 Patients who are well informed about their cancer treatment and aftercare are more likely to complete their therapy and are less anxious thereafter 5 6 Providing adequate information to cancer patients can reduce the psychological burden and improve patients’ QoL and their satisfaction with care 7 8 This is important since lymphoma and MM survivors report lower QoL compared to normative populations even years after diagnosis 9 10Up to now no studies have investigated the perceived level of and satisfaction with information provision in NHL HL and MM survivors If factors associated with information satisfaction are known health care providers can better give adequate information to those who need it which can contribute to an improved quality of care and QoL The aim of the present study was therefore to measure the perceived level of and satisfaction with information received by survivors of indolent NHL INHL aggressive NHL ANHL HL and MM and to identify associations with sociodemographic and clinical characteristics for each tumour typeThis study is part of a dynamic longitudinal populationbased survey among lymphoma and MM survivors registered within the Eindhoven Cancer Registry ECR of the Comprehensive Cancer Centre South and is embedded in PopulationBased HAematological Registry for Observational Studies The ECR records data on all patients who are newly diagnosed with cancer in the southern part of the Netherlands an area with 23 million inhabitants 18 hospital locations and 2 large radiotherapy institutes The ECR was used to select all patients who were diagnosed with NHL HL and MM between January 1 1999 and January 1 2009 We included all subtypes of indolent including chronic lymphocytic leukaemialike and aggressive B cell NHL HL and MM as defined by the International Classification of Diseases for Oncology3 codes 11Data collection took place in 2009 and was done within PROFILES Patient Reported Outcomes Following Initial treatment and Longterm Evaluation of Survivorship PROFILES is a registry for the study of the physical and psychosocial impact of cancer and its treatment from a dynamic growing populationbased cohort of both short and longterm cancer survivors PROFILES contains a large webbased component and is linked directly to clinical data from ECR Details of the data collection method have been previously described 12 Data from the PROFILES registry will become available for noncommercial scientific research subject to study question privacy and confidentiality restrictions and registration wwwprofilesregistrynl
Keywords:
.
|
Other Papers In This Journal:
- In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemia
- Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications
- Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement
- A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma
- Therapeutic implication of BAL in patients with neutropenia
- Effect of altered iron metabolism on markers of haem biosynthesis and intestinal iron absorption in mice
- Glucose-6-phosphate dehydrogenase deficiency and risk of diabetes: a systematic review and meta-analysis
- Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation
- Lung injury in a leukemia patient during mobilization of peripheral blood stem cells using granulocyte colony-stimulating factor alone
- Primary MALT lymphoma of the urinary bladder in the background of interstitial cystitis
- Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial
- Epidemiological profile of hemoglobinopathies in the Mauritanian population
- Efficacy and safety of deferasirox in myelodysplastic syndromes
- Haemoglobin Hokusetsu [β52 (D3)] Asp→Gly in German families associated with inclusion body
- Suggestion of response evaluation criteria in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML)
- Porcine antilymphocyte globulin (p-ALG) plus cyclosporine A (CsA) treatment in acquired severe aplastic anemia: a retrospective multicenter analysis
- Is the quantity of circulatory cell-free DNA in human plasma and serum samples associated with gender, age and frequency of blood donations?
- Searching for antigen epitope specificities in the monoclonal IgG molecules of patients with multiple myeloma. The description of a monoclonal antibody with a dynein-specific antigen epitope character
- A de novo ankyrin mutation (ANK1 Q109X) causing severe hereditary spherocytosis from preterm neonatal period
- Reusable terminal tap water filters for nosocomial legionellosis prevention
- Association between low uric acid levels and acute graft-versus-host disease
- Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects
- Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation
- Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR–ABL-positive acute lymphoblastic leukemia—retrospective analysis of Polish Adult Leukemia Group (PALG)
- High-risk AML complicated by pulmonary aspergillosis: successful treatment with nonmyeloablative stem cell transplantation and long-term administration of voriconazole
- Primary effusion lymphoma: successful treatment with highly active antiretroviral therapy and rituximab
- Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman’s disease
- Perioperative management of a patient with Fechtner syndrome
- Hemophagocytosis associated with leukemia: a striking association with juvenile myelomonocytic leukemia
- Long-term results of autologous stem cell transplantation for Hodgkin’s disease (HD) and low-/intermediate-grade B non-Hodgkin’s lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR)
- Storage time of red blood cell concentrates and adverse outcomes after cardiac surgery: a cohort study
- HLA-haploidentical hematopoietic stem cell transplantation with low-dose thymoglobulin GVHD prophylaxis for an adult T cell leukemia/lymphoma patient treated with pretransplant mogamulizumab
- Fatal chylous ascites, pericarditis and extensive venous thrombosis, due to an aggressive T cell non-Hodgkin lymphoma
- Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome
- Clonal relationship in multifocal non-Hodgkin’s lymphoma of mucosa-associated lymphoid tissue (MALT)
- Decrease in circulating percentage platelet microparticles during pregnancy—a different perspective
- Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information
- Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases
- Chronic immune thrombocytopenic purpura—who needs medication?
- Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
- Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting
- Maximum standard uptake value of 18 F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma
- Diffuse large B-cell lymphoma arising from donor lymphoid cells after renal and pancreatic transplantation
- FLT3 -ITD and MLL -PTD influence the expression of MDR-1 , MRP-1 , and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia
- Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors
- Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
- Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements
- Association of growth differentiation factor 15 (GDF15) polymorphisms with serum GDF15 and ferritin levels in β-thalassemia
- Suboptimal doses of low molecular weight heparin and acute venous thromboembolism. Data from the RIETE registry
- Suboptimal doses of low molecular weight heparin and acute venous thromboembolism. Data from the RIETE registry
- The novel compound OSI-461 induces apoptosis and growth arrest in human acute myeloid leukemia cells
- Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study
- Ciprofloxacin inhibits lipopolysaccharide-induced toll-like receptor-4 and 8 expression on human monocytes derived from adult and cord blood
- Constitutional pericentric inversion of chromosome 9 and hematopoietic recovery after allogeneic stem cell transplantation
- The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes
- Primary cardiac lymphoma mimicking atrial thrombus in a patient who underwent permanent pacemaker implantation
- Physician perceptions and preferences in the treatment of acquired immunodeficiency syndrome (AIDS)-related lymphoma
- Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia
- Therapy-related myelodysplastic syndrome/acute myeloid leukemia M2 and translocation (8;21)
- Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis
- Hereditary hemorrhagic telangiectasia patients can tolerate anticoagulation
- Concomitant plasmacytoma and B cell lymphoma with discordant light chain expression but clonal identity
- Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge
- Demyelination in the brain as a paraneoplastic disorder: candidates include some cases of leukemia and non-Hodgkin's lymphoma
- N -acetylcysteine reduces oxidative stress in sickle cell patients
- Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy
- Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy
- Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents
- Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial
- Hematologic malignancies with PCM1 - JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA , PDGFRB , and FGFR1
- Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients
- Frequency of the hemochromatosis gene ( HFE ) 282C→Y, 63H→D, and 65S→C mutations in a general Mediterranean population from Tarragona, Spain
- Focal splenic lesions in myeloproliferative disease: association with fatal outcome
- Stenotrophomonas maltophilia septicemia with pyomyositis in a chemotherapy-treated patient
- Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
- Durable complete remission after chemotherapy and rituximab in a case of Waldenström’s macroglobulinemia with pleuropulmonary involvement
- Human promoter mutations unveil Oct-1 and GATA-1 opposite action on Gfi1b regulation
- Human promoter mutations unveil Oct-1 and GATA-1 opposite action on Gfi1b regulation
- Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy
|